InvestorsHub Logo
Followers 67
Posts 16221
Boards Moderated 2
Alias Born 02/14/2011

Re: None

Monday, 10/15/2012 5:27:15 PM

Monday, October 15, 2012 5:27:15 PM

Post# of 152
10:52 AM Leerink Swan ups Eli Lilly (LLY +5.3%) to Outperform and raises sales estimates on the back of positive trial results for its gastric cancer treatment, ramucirumab. The firm thinks the recently released data shows encouraging potential for use on other tumor types, which could boost sales and lower the drug's overall marketing risk outlook.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LLY News